真实世界研究揭示HER2低表达并非独立预后因素，而是与临床病理特征相关。乳腺癌是全球女性最常见的恶性肿瘤之一。近年来，HER2低表达（HER2-low）乳腺癌作为一种新的治疗亚型备受关注。HER2-low乳腺癌是指HER2免疫组化（IHC）表达为1+ ...

尤其是HER2低表达（HER2-low）乳腺癌患者，由于其对新型抗体药物偶联物（ADC）显示出临床获益，这一亚群也越来越受到关注。尽管HER2-low乳腺癌的 ...

中山大学附属第一医院的研究人员为精准诊断 HER2-low 乳腺癌，开展相关研究，构建预测模型，助力临床决策。 乳腺癌是全球女性健康的 “头号杀手”，HER2 阳性肿瘤约占 15 - 20%，其余大多为 HER2 阴性肿瘤，其中 HER2-low 亚型占比达 40.4%。以往 HER2 阴性乳腺癌治疗 ...

“Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a new clinical subtype of breast cancer, benefiting from treatment with novel anti-HER2 antibody-drug ...

随着乳腺癌HER2三分类新时代的到来，HER2精准检测的重要性日益显著。而病理学家对HER2 IHC评分的判读具有主观性，当前亟需一种标准化的方法来确保 ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with AstraZeneca ...